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Summary Curcumin (diferuloylmethane), one of the main
components of the Indian spice turmeric, is known to
possess potent anti-inflammatory and anti-oxidant proper-
ties. In addition, curcumin has also been shown to have
in vitro and in vivo efficacy against a variety of malignan-
cies. In the current study we examined the cytotoxic effect
of curcumin on seven osteosarcoma (OS) cell lines with
varying degrees of in vivo metastatic potential. Curcumin
inhibited the growth of all OS cell lines tested with half-
maximal inhibitory concentration values ranging from 14.4
to 24.6 μM. Growth inhibition was associated with a dose
dependent increase in the number of apoptotic cells and
accumulation of cells in the G2/M phase of the cell cycle.
Curcumin treatment also resulted in cleavage of caspase-3
and poly adenosine diphosphate-ribose polymerase. More-
over, curcumin treatment was associated with an increase in
cellular levels of the apoptotic B-cell leukemia/lymphoma 2
(Bcl-2)-associated X protein and a decrease in cellular
content of the anti-apoptotic protein Bcl-2. In addition,
curcumin treatment also inhibited the migration of OS cell
lines. These data indicate that the potent cytotoxic activity
of curcumin on OS cell lines is mediated by induction of
apoptotic processes. Thus, curcumin has potential to be a
novel OS chemotherapeutic agent.
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Introduction
Osteosarcoma (OS) is a primary malignant bone tumor that
typically affects children and young adults and is an
extremely aggressive disease that is associated with a high
degree of lung metastases [1]. Consequently, patients have
historically been faced with a poor prognosis. In fact, 15–
20% of patients present with radiographically detectable
metastatic lesions at the time of diagnosis and 80% of
patients with localized tumors have microscopic foci [2].
Prior to the introduction of systemic chemotherapy,
osteosarcoma was treated with either amputation and/or
radiation therapy. However, the overall 2-year survival rates
after such treatment regimens ranged between 15–20% [3,
4]. Fortunately, several different clinical studies demon-
strated a significant improvement in patient outcome when
chemotherapy was administered before and after surgical
resection [5, 6]. Using this regimen 5-year survival rates are
now ~70% in patients who present with non-metastatic
disease or clinically undetectable metastatic lesions at
diagnosis. By contrast, the addition of chemotherapy to
surgical resection has not been able to improve the outcome
of patients who present with metastatic disease at diagnosis
and thus, the 5-year survival rate for these patients remains
at only 20% [1].
The most effective chemotherapeutic agents for OS
treatment include high-dose methotrexate, cisplatin and
doxorubicin [1]. The introduction of additional chemother-
apeutic agents, which have been shown to have anti-
neoplastic activity against osteosarcoma, such as ifosfamide
or etoposide, have unfortunately not been able to signifi-
cantly improve upon the current 70% 5-year survival rate
for patients with non-metastatic disease [1]. Moreover,
patients who relapse following administration of currently
approved agents have few other chemotherapeutic options
Invest New Drugs (2008) 26:289–297
DOI 10.1007/s10637-007-9099-7
D. K. Walters :R. Muff : B. Langsam :W. Born :B. Fuchs (*)
Laboratory for Orthopaedic Research,
Department of Orthopaedics, Balgrist University Hospital,
University of Zurich,
Forchstrasse 340,
8008 Zürich, Switzerland
e-mail: research@balgrist.ch
and have significantly lowered survival. Thus, it appears
that chemotherapeutic efficacy and patient survival has
reached a plateau with currently available chemotherapeutic
agents. The use of high-dose methotrexate, cisplatin,
doxorubicin and/or etoposide and ifosfamide is also
associated with both acute and long-term toxicities [7–9].
Therefore, the development and/or discovery of novel
chemotherapeutic agents that improve survival rates and
decrease toxicity are of the utmost importance.
Curcumin (diferuloylmethane), a polyphenol, is one of
the main components of the Indian curry spice turmeric [10,
11] and is known to be a powerful anti-oxidant with strong
anti-inflammatory properties [12, 13]. Recently, curcumin
has also been shown to possess potent anti-neoplastic
activity (reviewed in [14, 15]) against a number of tumors
including prostate, breast and colon cancer [16–18]. To date
the exact mechanism(s) underlying curcumin’s anti-
neoplastic activity has yet to be determined. However,
curcumin has been shown to affect numerous signaling
pathways and the curcumin-induced cytotoxicity has been
hypothesized to vary among cell types [14]. Yet, curcumin
has demonstrated in vivo efficacy in a number of tumor
models and it has recently been successfully tested in Phase
I clinical trials for the treatment of colon cancer [19].
Consequently, we were interested in evaluating the anti-
cancer effects of curcumin on human osteosarcoma cell
lines in vitro.
Materials and methods
Cell lines and reagents
The human OS cell lines SAOS-2 (HTB-85), U2OS (HTB-
96), HOS and 143B cells were obtained from the American
Type Culture Collection (Rockville, MD, USA). LM5 cells
were kindly provided by E.S. Kleinerman (M.D. Anderson
Cancer Center, Houston, TX, USA). Hu09 and Hu09 m132
cells were provided by Dr. M. Tani (National Cancer Center
Hospital, Tokyo, Japan), MG-63 cells were provided by Dr.
G. Sarkar (Mayo Clinic, Rochester, MN, USA) and MG-63
M8 cells were provided by Dr. W.T. Zhu (Tongji Hospital,
Huazhong University of Science and Technology, Wuhan,
China). Normal fibroblasts were obtained from Coriell Cell
Repositories (Camden, NJ, USA). All cell lines, except
Hu09 and Hu09 m132 were cultured in Dulbecco’s
Modified Eagle Medium (4.5 g/l glucose)/Ham F12 (1:1;
Invitrogen, Carlsbad, CA, USA) supplemented with 10%
fetal calf serum (FCS), 1 unit/ml penicillin G, and 1 μg/ml
streptomycin. Hu09 and Hu09 m132 cells were cultured in
Roswell Park Memorial Institute medium supplemented
with 10% FCS, 1 unit/ml penicillin G, and 1 μg/ml
streptomycin. All cells were cultured at 37°C in a humidified
atmosphere of 5% CO2. Z-VAD-FMK, a pancaspase
inhibitor, was purchased from Becton, Dickinson and Co.
(BD) Pharmingen (San Diego, CA, USA). Curcumin was
purchased from Sigma-Aldrich Chemical Co. (Buchs,
Switzerland).
Cytotoxicity assay
Three thousand cells per well were plated in 96-well plates
and allowed to adhere overnight. Various concentrations of
curcumin were added the following day. Cytotoxicity was
measured 72 h later with water-soluble tetrazolium salt
(WST-1) reagent (Roche,Mannheim, Germany), as previously
described [20]. Percentage growth inhibition was calculated
by dividing the absorbance of curcumin treated cells by that
of untreated (control) cells and multiplying by 100. Statistical
differences were determined with the Student’s t-test.
Cell viability assay
Cell viability was measured using Guava Viacount reagent
and analyzing the cells on a Guava EasyCyte machine
(Guava Technologies Inc., Hayward, CA, USA). Cells
(1.5×105) were plated in six-well plates and allowed to
adhere overnight. The following day curcumin was added
at indicated concentrations to the medium. Twenty-four
hours later the cell culture medium was removed, cells were
washed 1× with phosphate-buffered saline (PBS) and
trypsinized. The cells were then washed 1× with PBS and
resuspended in 500 μl of PBS. A 20 μl aliquot of cell
suspension was then incubated with 180 μl of Viacount
reagent for 5 min at room temperature (RT). Cells were
then analyzed on a Guava EasyCyte machine using the
Viacount Acquisition Module (Guava Technologies Inc.,
Hayward, CA, USA).
Cell cycle analysis
One hundred fifty thousand cells were plated in six-well
plates and allowed to adhere overnight. Indicated curcumin
concentrations were added the following day. Following a
24 h incubation, the cell culture medium was removed,
cells were washed 1× with PBS and then trypsinized. After
trypsinization cells were washed 1× with cold PBS. Cells
were then resuspended in 300 μl of cold PBS and 1 ml of
ice cold ethanol was added dropwise while vortexing. Cells
were then incubated overnight at −20°C. The following day
cells were washed 1× with cold PBS. Cells were then
resuspended in 500 μl of fluorescence-activated cell sorting
solution (38 mM NaCitrate pH 7.5, 69 μM propidium
iodide (PI), 10 μg RNase) and incubated in the dark at
37°C for 30 min. Samples were then analyzed on a Guava
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EasyCyte machine using the Cell Cycle Acquisition
Module (Guava Technologies Inc., Hayward, CA, USA).
Detection of apoptosis
Microscopic analysis
Apoptosis cells were stained with an annexin-V-fluorescein
isothiocyanate (FITC) detection kit and necrotic cells were
visualized by PI staining (BD Pharmingen, San Diego, CA,
USA). One hundred fifty thousand cells were plated in six-
well plates and allowed to adhere overnight. Indicated
curcumin concentrations were added the following day.
Twenty-four hours later the cell culture medium was removed
and the cells were washed 1× with PBS and then 1× with
annexin binding buffer. The cells were then incubated for
15 min at RTwith annexin-V-FITC and PI in annexin binding
buffer. The cells were washed 1× and visualized using an
Eclipse E600microscope (Nikon, Egg, Switzerland) equipped
with a ×10 objective, a Nikon Y-FL fluorescence illumination
with appropriate filters and a Kappa DX20 camera (Kappa
opto-electronics GmbH, Gleichen, Germany).
Guava EasyCyte analysis
Apoptosis was also examined with a Guava Nexin Kit
containing annexin-V-PE and 7-amino-actinomycin D (7-
AAD) for staining of apoptotic and necrotic cells, respectively
(Guava Technologies Inc., Hayward, CA, USA). Briefly,
150,000 cells were plated in six-well plates and allowed to
adhere overnight. Curcumin was added the following day at
indicated concentrations. Twenty-four hours later the cell
culture medium was removed and the cells were washed
1× with PBS and trypsinized. The cells were then washed
1× with annexin binding buffer and then incubated for 20 min
on ice in 50 μl annexin binding buffer containing annexin-V-
PE and 7-AAD. Following incubation, 450 μl of Nexin buffer
was added to each tube and the cells were then analyzed on a
Guava EasyCyte machine using the Nexin Acquisition
Module (Guava Technologies Inc., Hayward, CA, USA).
Wound healing migration assay
Cells were seeded in 24-well plates at approximately 40%
of confluence. At confluency, a wound (0.6–1 mm wide
and approximately 1 cm in length) was applied with a
sterile pin. Cell debris was removed by washing twice with
cell culture medium. A homogenous wound area free of cell
debris was then marked under the microscope (Nikon
Diaphot) with a circle using the Nikon object marker
device. The widths of the wounds were measured immedi-
ately after wounding (Do) in the middle of the circle using a
Nikon ocular with a graded 1 mm scale. After incubation at
37°C for 24 h in the absence and presence of indicated
concentrations of curcumin, the wound widths were
measured again (Dt) in the marked area and the migratory
rate (μm/h) was calculated by the equation Do−Dt/2×24 h.
Immunoblotting
Cells (1×106) were lysed on ice with lysis buffer consisting
of 50 mM trishydroxymethylaminomethane pH 7.5,
150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.1%
sodium dodecyl sulfate (SDS). Lysates were cleared of
insoluble material by centrifugation at 14,000 rpm, 4°C for
10 min. Protein content was measured with a standard
Bradford assay and 80 μg of total protein was resolved by
SDS-polyacrylamide gel electrophoresis. Resolved proteins
were then transferred to Immobilon-P membranes for
immunoblotting. Poly adenosine diphosphate -ribose poly-
merase (PARP), B-cell leukemia/lymphoma 2 (Bcl-2), Bcl-
2-associated X protein (BAX), and caspase-3 were detected
using PARP, Bcl-2, BAX and caspase-3 antibodies (Cell
Signaling Technology, Beverly, MA, USA). Actin was
detected using an actin antibody (Chemicon, Dietikon,
Switzerland). Horseradish peroxidase secondary antibodies
were obtained from Santa Cruz Biotechnology (Santa Cruz,
CA, USA).
Results
Curcumin inhibits the growth of osteosarcoma cell lines
Incubation with curcumin resulted in growth inhibition of
all seven OS cell lines tested and the half-maximal
inhibitory concentration (IC50) of curcumin ranged from
14.4 to 24.6 μM (Fig. 1a). The cell lines (Hu09 m132,
LM5, MG-63 M8, and 143B) possessing greater in vivo
metastatic potential than their respective parental cell lines
(Hu09 WT, SAOS-2, MG-63 WT and HOS) were found to
be relatively equal in their sensitivity to curcumin. Thus,
the effect of curcumin appeared to be comparable among all
OS cell lines tested. The mechanism(s) of action of
curcumin were further assessed, as discussed below, using
all cell lines and the results were found to be representative
for all cell lines investigated. However, for simplicity, the
figures display the results for the U2OS and SAOS-2 cell
lines only.
Curcumin treatment decreases OS cell viability
The effect of a drug can be cytotoxic or cytostatic. Thus, we
next wanted to determine how curcumin was exerting its
growth inhibitory effect on OS cell lines. In initial experi-
ments we examined the effect of curcumin on OS cell line
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viability using an assay that solely distinguishes viable cells
from necrotic cells. As shown in Fig. 1b, treatment of
U2OS and SAOS-2 cells with increasing concentrations of
curcumin for 24 h resulted in a dose-dependent decrease in
viable cells and thus, indicated a cytotoxic effect of
curcumin on OS cells.
Curcumin induces apoptosis of OS cell lines
As discussed above, treatment of OS cell lines with
curcumin resulted in a decrease in the total number of
viable cells. However, the viability assay can only
distinguish between viable and necrotic cells and can not
distinguish viable cells from early apoptotic cells. Conse-
quently, some early apoptotic cells may be identified as
viable cells. Thus, we next wanted to use a more specific
apoptosis assay in order to determine whether curcumin
was indeed inducing apoptosis of OS cell lines. Early
apoptosis is associated with translocation of phosphatidyl-
serine (PS) to the cell surface and can be detected via
annexin-V staining due to the high affinity of annexin-V for
PS [21]. To assess curcumin-induced apoptosis of OS cell
lines, we treated OS cell lines with increasing concen-
trations of curcumin for 24 h, then incubated the cells with
annexin-V-FIT-C and PI and observed the cells microscop-
ically. With all cell lines, a dose-dependent increase in the
number of annexin-V-FITC stained apoptotic cells was
observed following treatment with increasing concentra-
tions of curcumin, whereas the number of PI-stained
necrotic cells remained unchanged (U2OS results shown
in Fig. 2a). Curcumin-induced apoptosis was also quanti-
fied by flow cytometry using a Guava EasyCyte machine
(Fig. 2b–d). Increasing concentrations of curcumin de-
creased the number of viable cells (annexin-V negative, 7-
AAD negative) and increased the number of early apoptotic
cells (annexin-V positive, 7-AAD negative cells). When the
results of the apoptosis assay are compared to the viability
assay, we observed apoptotic cells at concentrations that
showed no effect in the viability assay. Thus, some
apoptotic cells were indeed identified as viable cells using
the viability assay and a more specific apoptosis assay
reveals the apoptosis-inducing mechanism of curcumin. An
increase in late apoptotic/necrotic cells (annexin-V positive,
7-AAD positive) cells was only observed after treatment
with the two highest concentrations of curcumin. The
absence of a significant population of late apoptotic/
necrotic cells upon microscopic analysis may be attributed
to cell detachment.
Curcumin induces cell cycle arrest in the G2/M phase
Cell cycle distribution of U2OS and SAOS-2 cells,
following a 24 h treatment with increasing concentrations
of curcumin, was assessed by flow cytometry. Treatment
with curcumin resulted in a dose-dependent increase in the
number of cells in the G2/M phase and a decrease in the
number of cells in the G1 phase indicating a curcumin-
induced G2/M phase arrest (Fig. 3). Although a G2/M phase
arrest does not always correlate with an induction of
apoptosis, in this case the G2/M phase arrest results
Fig. 1 Curcumin inhibits
the growth of OS cell lines and
reduces cell viability. a Dose-
dependent growth inhibition in
indicated OS cell lines following
72-h curcumin treatment.
Values represent mean±SEM
(n=3). Curcumin IC50 values for
all cell lines tested are displayed
in the accompanying table.
b U2OS and SAOS-2
cells were treated with increas-
ing concentrations of curcumin.
Twenty-four hours later
cell viability was analyzed using
Guava Viacount reagent.
Values represent mean±SD
(n=3)
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correlate with the observed curcumin-induced apoptosis in
Fig. 2c.
Effect of curcumin on apoptotic signaling pathways
Caspases, a family of cysteine acid proteases, are proteo-
lytically activated and then cleave and activate other
caspases or cleave and thereby inactivate key cellular
proteins such as PARP [22]. Treatment of U2OS and
SAOS-2 cells with indicated concentrations of curcumin
resulted in a dose-dependent decrease in procaspase-3 and a
dose-dependent increase in PARP cleavage (Fig. 4a). A
2-h pre-incubation of the cells with the pancaspase inhibitor
Z-VAD-FMK prior to curcumin treatment significantly
inhibited the decrease in procaspase-3 and PARP cleavage
(Fig. 4b).
In addition to activation of the caspase cascade, curcumin
has also been shown to decrease cellular levels of the anti-
Fig. 3 Curcumin induces G2/M
cell cycle arrest of OS cell lines.
U2OS and SAOS-2 cells were
treated with increasing concen-
trations of curcumin. Twenty-
four hours later cells were
stained with PI and analyzed for
DNA content. Values represent
mean±SD (n=3)
Fig. 2 Curcumin induces apoptosis of OS cells. a U2OS cells were
treated with increasing concentrations of curcumin. Twenty-four hours
later cells were stained with annexin-V-FITC and PI to visualize
apoptotic and necrotic cells, respectively. Figures are representative of
three independent experiments. b–d U2OS and SAOS-2 cells were
treated for 24 h with indicated curcumin concentrations and 24 h later
cells were stained with Annexin-V-PE and 7-AAD and analyzed by
flow cytometry. b displays the number of viable cells (Annexin-V
negative, 7-AAD negative cells), c displays the number of early
apoptotic cells (Annexin-V positive, 7-AAD negative) and d displays
the number of late apoptotic/necrotic cells (Annexin-V positive,
7-AAD positive cells). Values represent mean±SD (n=3)
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apoptotic protein Bcl-2 and to increase cellular levels of the
apoptotic protein BAX [23]. U2OS cells were therefore
treated with increasing concentrations of curcumin and the
cell lysates were subjected to western blot analysis. As
shown in Fig. 4c, curcumin treatment indeed decreased
cellular levels of Bcl-2 and increased cellular levels of BAX.
Curcumin inhibits OS cell line migration
The effect of curcumin on migration and adhesion is well
known [24, 25]. Thus, we next wanted to determine if
curcumin would inhibit the migration of OS cell lines in the
wound healing migration assay. As shown in Fig. 5, wound
healing migration of U2OS and SAOS-2 cells was not
affected by 6.25 μM curcumin during a 24 h treatment.
However, migration of SAOS-2 cells was half-maximally
inhibited with 12.5 μM curcumin, while migration of
U2OS cells was half-maximally inhibited with 25 μM
curcumin. Similar results were obtained with all other cell
lines tested. At 50 μM migration was almost completely
blocked in all cell lines. At this concentration, but not
below all cell lines started to partly detach and had a
rounded appearance.
Curcumin can be used in combination with cisplatin
In order to determine whether curcumin could be used in
combination with current OS chemotherapeutic agents,
U2OS cells were incubated with increasing concentrations
of doxorubicin or cisplatin in the absence and presence of
Fig. 4 Effect of curcumin on
apoptotic signaling pathways.
a U2OS and SAOS-2 cells were
treated for 24 h with indicated
curcumin concentrations and
cell lysates were then subjected
to immunoblot analysis for
procaspase-3, PARP and actin.
b U2OS and SAOS-2 cells were
pre-treated for 2 h with 50 μM
of the general caspase inhibitor
Z-VAD-FMK prior to curcumin
addition. Twenty-four hours
following curcumin treatment
cells were harvested and cell
lysates subjected to immunoblot
analysis for procaspase-3, PARP
and actin. c U2OS and SAOS-2
cells were treated for 24 h with
curcumin at indicated concen-
trations and cell lysates were
then subjected to immunoblot
analysis for BAX, Bcl-2
and actin
Fig. 5 Curcumin inhibits OS cell line migration. Confluent cells were
wounded as described in the “Materials and methods” and incubated
at 37°C in the absence and presence of indicated concentrations of
curcumin. Wound closure was measured after 24 h and migratory rates
calculated as described. Migratory rates of untreated controls were set
to 100%. Values represent mean±SEM (n=4)
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15 μM curcumin, a concentration produces a 10% growth
inhibition after a 72 h incubation. The combined treatment
of cells with curcumin and doxorubicin did not have an
additive effect compared to treatment with either drug alone
(Fig. 6a). However, additive cytotoxicity was observed with
curcumin and cisplatin (Fig. 6b).
Discussion
The discovery and development of novel chemotherapeutic
agents that can improve OS survival rates and/or lower the
occurrence of toxic side effects experienced with currently
approved agents is of the utmost importance. Recently,
several reports have described the potent anti-neoplastic
activity of curcumin against several diverse types of
malignancy. Consequently, significant interest in curcumin
as a potential anti-cancer drug has been generated and
curcumin has recently been extensively tested in Phase I
clinical trials [26]. In this study we examined the anti-
neoplastic activity of curcumin against OS cell lines. Initial
experiments demonstrated that all OS cell lines tested were
remarkably sensitive to the effects of curcumin with IC50s
ranging from 14.4–24.6 μM. Similar IC50 values were
reported following curcumin treatment of HeLa and MCF-7
cell lines [27] and thus, our inhibitory concentrations are
within previously reported values.
The anti-proliferative activity of curcumin has previous-
ly been attributed to curcumin-induced apoptosis [28–30].
Our step-by-step examination using viability and apoptosis
assays revealed that curcumin indeed induces apoptosis of
OS cell lines. Investigation of the signaling pathways
activated by curcumin confirmed that curcumin induces
apoptosis of OS cell lines and that caspases are involved in
this process. However, curcumin has been previously
shown to affect numerous diverse signaling pathways
(reviewed in [14]). Moreover, the apoptotic process is
known to involve an orchestrated series of signaling events
and thus, curcumin-induced apoptosis of OS cell lines may
involve additional signaling pathways. Two proteins that
have previously been shown to be involved in curcumin-
induced apoptosis are Bcl-2 and BAX. Proteins of the Bcl-2
family are key regulators of apoptosis while BAX belongs
to the pro-apoptotic group [31]. Bcl-2 exerts its anti-
apoptotic effects via inhibition of mitochondrial cyto-
chrome c release. By contrast, BAX asserts a pro-apoptotic
effect by interacting with membrane pore proteins to
increase cytochrome c release [32, 33]. Curcumin treatment
of diverse cell types has recently been shown to result in
decreased Bcl-2 cellular levels and increased cellular levels
of BAX [34, 35]. Moreover, Anto et al. [36] and Shankar
and Srivastava [23] demonstrated that curcumin-induced
regulation of Bcl-2 and BAX is essential for curcumin-
induced apoptosis. In the current study, curcumin treatment
of OS cell lines also resulted in decreased and increased
cellular levels of Bcl-2 and BAX, respectively. Conse-
quently, these findings indicate that Bcl-2 and BAX are also
critical regulators of curcumin-induced apoptosis in OS cell
lines.
The ability of curcumin to inhibit cell migration and
adhesion is well known [24, 25]. Indeed, in the current
study curcumin treatment of OS cell lines was also found to
inhibit cell migration. The exact mechanism of curcumin-
induced cell migration inhibition is not known but
curcumin has been shown to affect proteins involved in
cell-cell adhesion such as ß-catenin and E-cadherin [14].
Based on curcumin’s ability to inhibit cell migration and
adhesion in vitro, it is also believed that curcumin may be
able to inhibit the migration of established malignancies in
vivo and thus, decrease the formation of metastases.
According to current European and American Osteosar-
coma Study Group treatment guidelines, OS patients
typically receive 10 weeks of neo-adjuvant therapy,
undergo surgical resection with wide margins and then
receive adjuvant therapy based on their histological
response to neo-adjuvant treatment. In order to improve
overall patient survival, novel agents must either be
sufficiently potent to take the place of existing therapies
Fig. 6 Curcumin demonstrates an additive effect with cisplatin. a
U2OS cells were treated for 72 h with either increasing concentrations
of doxorubicin alone (filled square) or in combination with 15 μM
curcumin (filled triangle). Viable cells were then determined with a
WST-1 assay. Values represent mean±SEM (n=3). b U2OS cells were
treated with either increasing concentrations of cisplatin alone (filled
square) or in combination with 15 μM curcumin (filled triangle).
Viable cells were then determined with a WST-1 assay. Values
represent mean±SEM (n=3)
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or must be compatible with previously established regi-
mens. In this study we examined the compatibility of
curcumin in combination with doxorubicin and cisplatin
and of note, the effect of curcumin was shown to be
additive with the effect of cisplatin. By contrast, the effect
of curcumin was not found to be additive with the effect of
doxorubicin, yet curcumin did not inhibit the cytotoxic
effect of doxorubicin. The combination effect of curcumin
with cisplatin and lack of an additive effect with doxoru-
bicin was also reported by Notarbartolo et al. [37] with
human hepatic cancer cells. In this report, the authors
discuss that curcumin is known to interfere with nuclear
factor-kappa B (NF-κB) activation and that other reports
indicate that doxorubicin requires NF-κB activation in
order to induce its cytotoxic effect. Consequently, it has
been suggested that curcumin may diminish the antitumor
effect of doxorubicin. Nonetheless, in vitro curcumin
appears to be compatible with agents used for treatment
of osteosarcoma and supports further investigation into its
potential for clinical application. However, pre-clinical and
clinical investigations must pay particular attention to
synergistic and sub-additive effects of curcumin when used
in combination with current therapeutic agents.
The current study and numerous additional studies have
demonstrated the potent anti-neoplastic properties of cur-
cumin. Furthermore, animal models and pre-clinical trials
have reported no adverse effects following administration
of curcumin. However, widespread clinical application of
curcumin has been limited due to poor aqueous solubility
and low systemic bioavailability. Nevertheless, enthusiasm
for clinical use of curcumin continues and recently Bischt
et al. described the development and successful testing of
aqueous soluble nanocurcumin in vitro [38]. Consequently,
optimism continues for the clinical potential of curcumin
for treatment of OS and various other malignancies.
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